In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

New oral anticoagulants - clinical challenges

Cardiovascular Pharmacology and Pharmacotherapy

As expected, there were hardly any seats left in the session “New oral anticoagulants / clinical challenges” due to the timeliness of the topic and the list of high ranking speakers.
Chaired by Dr. Steffel (Zurich, Switzerland) and  Dr. Andreotti  (Rome/Italy), Dr. Ottani (Piangipane/Italy) started off the session by explaining the necessity of, and summarizing the modalities for bleeding risk stratification.

Dr. Svensson from Malmo (Sweden) continued on the possibilities of monitoring new oral anticoagulants (NOACs) with a specific emphasis on situations in which it makes sense to do so – and when not.
Using 4 patient case scenarios, Dr. Halvorsen (Oslo, Norway) explained the management of patients undergoing percutaneous coronary interventions or electrophysiological testing, with a special note on peri-interventional anticoagulation regimens and the necessity for triple anticoagulation.
Finally, Dr. Verheugt from Amsterdam (Netherlands) explained management issues in patients undergoing major and/or urgent surgical procedures, thereby also touching on the possibilities as well as limitations and risks of antagonizing anticoagulation therapy (both vitamin K antagonists as well as NOACs).

Lively discussion amongst the audience, chairpersons and speakers reflected both the high interest in these novel substances, and the desire to use them correctly – even in tricky situations – to maximize patient benefit.




New oral anticoagulants - clinical challenges

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.